215 related articles for article (PubMed ID: 18452850)
21. The science and art of prostate cancer screening.
Yao SL; Lu-Yao GL
J Natl Cancer Inst; 2011 Mar; 103(6):450-1. PubMed ID: 21350220
[No Abstract] [Full Text] [Related]
22. Prostate cancer screening; is this a teachable moment?
Brawley OW
J Natl Cancer Inst; 2009 Oct; 101(19):1295-7. PubMed ID: 19720970
[No Abstract] [Full Text] [Related]
23. Diagnosis and treatment of patients with prostate cancer: the nurse's role.
Turner B
Nurs Stand; 2007 Jun 6-12; 21(39):48-56; quiz 58. PubMed ID: 17569378
[TBL] [Abstract][Full Text] [Related]
24. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
25. [Prostate cancer screening: no proof of the benefit].
Laplanche A; Hill C
Presse Med; 2009 Oct; 38(10):1393-5. PubMed ID: 19647979
[No Abstract] [Full Text] [Related]
26. A risk-stratified approach to prostate-specific antigen screening.
Keto CJ; Freedland SJ
Eur Urol; 2011 Apr; 59(4):506-8. PubMed ID: 21292387
[No Abstract] [Full Text] [Related]
27. Prostate specific antigen and screening for early prostate cancer.
Davidson P
N Z Med J; 2001 Apr; 114(1129):150. PubMed ID: 11400919
[No Abstract] [Full Text] [Related]
28. Controversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues.
Ito K
Int J Urol; 2009 Sep; 16(9):711-12. PubMed ID: 19777638
[No Abstract] [Full Text] [Related]
29. Prostate-specific antigen dynamics and prostate cancer diagnosis.
Bartoletti R
Eur Urol; 2009 Nov; 56(5):761-2; discussion 763. PubMed ID: 19665286
[No Abstract] [Full Text] [Related]
30. Prostate cancer: 4. Screening.
Meyer F; Fradet Y
CMAJ; 1998 Oct; 159(8):968-72. PubMed ID: 9834724
[No Abstract] [Full Text] [Related]
31. New trial data do not end the PSA screening debate.
Vastag B
J Natl Cancer Inst; 2009 Jun; 101(12):844-5. PubMed ID: 19509364
[No Abstract] [Full Text] [Related]
32. The role of increasing detection in the rising incidence of prostate cancer.
Potosky AL; Miller BA; Albertsen PC; Kramer BS
JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
34. Re: Is a screening interval of every 4 years for prostate cancer acceptable?
Roobol MJ; Schröder FH
J Natl Cancer Inst; 2008 Feb; 100(3):222; author reply 223-4. PubMed ID: 18230797
[No Abstract] [Full Text] [Related]
35. Prostate cancer: recent trends in Korea.
Chi BH; Chang IH
Urol Int; 2010; 85(1):88-93. PubMed ID: 20616537
[TBL] [Abstract][Full Text] [Related]
36. Screening for prostate cancer: the case for.
Malone P
Ann R Coll Surg Engl; 2005 Mar; 87(2):88-9; discussion 88. PubMed ID: 15826414
[No Abstract] [Full Text] [Related]
37. Impact of screening on incidence and mortality of prostate cancer in the United States.
Potosky AL; Feuer EJ; Levin DL
Epidemiol Rev; 2001; 23(1):181-6. PubMed ID: 11588846
[TBL] [Abstract][Full Text] [Related]
38. Eradication of a disease: how we cured symptomless prostate cancer.
Tannock IF
Lancet; 2002 Apr; 359(9314):1341-2. PubMed ID: 11965297
[No Abstract] [Full Text] [Related]
39. Prostate cancer: A challenge for screening.
Donnell RF
Surg Oncol Clin N Am; 1999 Oct; 8(4):693-702, vii. PubMed ID: 10452935
[TBL] [Abstract][Full Text] [Related]
40. Cancer trends in the United States--a view from Europe.
Quinn MJ
J Natl Cancer Inst; 2003 Sep; 95(17):1258-61. PubMed ID: 12953072
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
